WHA Statement at the WHO Executive Board

The Executive Board of the World Health Organization (WHO) met in January 2022, on the agenda was the creation of a new Global Health Sector Strategy (GHSS) on viral hepatitis, HIV and STI’s. The World Hepatitis Alliance, as a non-state actor to WHO submitted the below statement to the discussion. 

 

 
Statement at the 150th session of the WHO Executive Board by the World Hepatitis Alliance, an international network of 314 organisations in 100 countries.

Agenda Item 7.8 The global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections

The World Hepatitis Alliance welcomes the new Global Health Sector Strategy on HIV, Viral Hepatitis, and Sexually Transmitted Infections.

Viral hepatitis is one of the deadliest health crises of our time, claiming more than a million lives every year. This strategy is vital for holding countries accountable for their commitment. Hepatitis elimination will not happen without a concerted effort from all stakeholders, with the active involvement of civil society and the affected community, backed by political will.

Low- and middle-income countries that often have fewest resources and highest disease burden have a mountain to climb to reach elimination. They cannot be expected to these goals alone. The global health and donor community must do more to support their efforts and health systems must integrate hepatitis elimination throughout their services including cancer prevention and maternal and child health.

Hepatitis Can’t Wait.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close